Atul Ltd 2010-11

Atul Ltd | Annual Report 2010-11 Pharma & Inters Products APIs, API intermediates, Others is estimated at US$ 20 bn and is growing at about 10%. There are about 50 major companies, which dominate the world marketplace. The main user industry, namely, Healthcare, is growing well because of the increasing awareness about diseases and health. The Company along with Atul Bioscience will participate in this growth by i) debottlenecking capacities, ii) introducing new products and iii) significantly improving efficiencies. It will also form long-term alliances with other companies. Prices of many products come down significantly in a short time. Fluctuations in foreign exchange will impact sales realizations. Pharma & Inters product group mainly comprises API intermediates and a few APIs used by Pharmaceutical industry under five broad therapeutic categories, namely, anti- depressant, anti-diabetic, anti-infective and anti-retroviral. The group comprises 27 products and is relatively a new introduction to the product portfolio of Atul. The Company is not currently engaged in formulations of APIs. During the year, sales of the product group increased by 34% to ` 184 crores. Export sales increased by 43% to ` 95 crores and formed 51% of the total. Atul Bioscience made its first sales, and the Company is expected to focus only on the products required by Pharmaceutical industry. World market for pharmaceuticals is estimated at US$ 700 bn and is growing at about 4%. Indian market for such products